S6 Kinase Inhibitors
S6 Kinase (specifically S6K1 and S6K2) is a family of serine/threonine kinases that act as key downstream effectors of the mTORC1 signaling pathway. S6K1 is the most well-characterized isoform and plays a fundamental role in regulating protein synthesis, cell size, and glucose metabolism. Upon activation by mTORC1-mediated phosphorylation at Thr389, S6K1 phosphorylates several substrates, most notably the ribosomal protein S6, which enhances the translation of specific mRNA transcripts. It also regulates the activity of eukaryotic initiation factor 4B (eIF4B) and the degradation of PDCD4, a negative regulator of translation. Dysregulation of S6K1 signaling is frequently observed in various cancers, including breast, prostate, and lung cancer, and is often associated with poor prognosis and resistance to endocrine therapy.
Beyond oncology, S6K1 is a critical player in metabolic diseases; it mediates a negative feedback loop where it phosphorylates insulin receptor substrate 1 (IRS1) on inhibitory serine residues, leading to insulin resistance and type 2 diabetes. The development of S6 Kinase inhibitors has gained momentum as a strategy to overcome the limitations of rapalogs. While rapalogs inhibit mTORC1, they often lead to the loss of the S6K1-mediated negative feedback on IRS1, resulting in the compensatory activation of Akt. Direct S6K1 inhibitors aim to block the pro-growth effects of the pathway while potentially avoiding some of the metabolic complications associated with upstream inhibition. These inhibitors are primarily classified as ATP-competitive small molecules.
PF-4708671 was one of the first isoform-selective S6K1 inhibitors developed and has been used extensively as a research tool. More recently, several other compounds have entered preclinical and early clinical development. A significant challenge in targeting S6K is the high degree of homology between S6K1 and S6K2, as well as other AGC family kinases like p90RSK, which can lead to off-target effects. Additionally, the redundancy between S6K1 and other signaling nodes can limit the efficacy of monotherapy. Current research is focused on the use of S6K inhibitors in combination with PI3K or Akt inhibitors to provide a more robust blockade of the pathway and prevent compensatory signaling.
There is also interest in the role of S6K2 in regulating cell survival and its potential as a distinct therapeutic target. As the structural basis for S6K activation becomes clearer, the design of more potent and selective inhibitors continues to evolve, offering new possibilities for treating both cancer and metabolic disorders characterized by overactive mTOR signaling.
